The June 10, 2007, issue of the Journal of Clinical Oncology may have represented a watershed of sorts in the progress of research on integrative cancer therapies. Not only did the lead article 1 conclude that a good diet plus exercise results in longer survival among stage I through III breast cancer patients while diet and exercise separately had lesser effects, but a second article reported finding links between depression, immunity, and survival in hepatobiliary cancer. 2 In addition, a third article found that early-stage breast cancer patients who received exercise interventions based on instruction books plus pedometers reported better quality of life than those who did not exercise. 3 Of the 3 articles, the one that is probably the most exciting is the diet and exercise study. This study analyzed 1490 members of the control group of the Women's Healthy Eating and Living (WHEL) Study, which is still in process. WHEL was designed to test whether women who were instructed in the use of plant-based diets would have a better survival rate than those in the nonintervention control group (which they did not, perhaps due to the absence of any significant lowering of dietary fat or calories in the diet intervention group). 4 As an analysis of the control group, this study did not shed light on the intervention, but it did powerfully illustrate the possibilities of an intervention that stresses a holistic approach to health rather than concentrating on a single factor. The control group was observed prospectively for nearly 9 years to assess the relationships of mortality to consumption of vegetables and fruit and other dietary categories, physical activity (PA), and body mass index (BMI).
In univariate analyses, vegetable and fruit (VF) intake and PA were significantly related to survival. The BMI was related to survival, with both underweight (BMI <20 kg/m 2 ) and obese (BMI >30 kg/m 2 ) women having lower survival than normal and overweight women. The authors found that neither fat, fiber, nor total calories were related to survival.
The authors then divided the study group into 4 subgroups, which I call "lifestyle groups." The high VF/high PA lifestyle group had more than 5 vegetable or fruit servings and a PA level equivalent to walking 6 days a week for 30 minutes a day or more. The low VF/low PA group ate the worst diets and had a PA level slightly less than half that of the high PA group. The other groups were high VF/low PA and low VF/high PA. The high VF/ high PA group had a mortality rate that was less than half that of the 3 other groups. I would point out that this was a very healthy group of women, eating 7.6 servings of vegetables and fruits daily and doing exercise that was equivalent to a little more than 80 minutes per day of walking (I suspect that they actually exercised more intensively for a shorter period).
However, the real shocker came when the study team analyzed how obese women did who were in the different VF/PA groups. In the 3 groups with lower vegetable or fruit consumption or less exercise, obese women had a higher percentage mortality than the nonobese women did. However, the high VF/high PA lifestyle apparently protected women from the otherwise negative effects of obesity! The women with BMI >30 kg/m 2 in this group had the same mortality rate as those with lower BMIs. This good news was somewhat moderated by the authors' observation that obese women were only about half as likely as nonobese women to be in the high VF/high PA lifestyle group.
Another result was rather surprising in the light of the recent publication of the Women's Intervention Nutrition Study (WINS) randomized study. 5 In the WINS, a low-fat diet intervention reduced recurrences in breast cancer patients, with the unexpected finding that the diet was more effective in reducing recurrences in patients with estrogen-receptor negative (ER-) tumors and less effective with patients with ER+ tumors. In this WHEL control group, the high VF/high PA lifestyle significantly reduced mortality for patients with ER+ tumors (regardless of progesterone status) but made no difference at all for the ER-, progesterone receptor negative (PR-) patients. Interestingly, a 2006 study of surgical specimens found that expression of COX-2 mRNA was higher in ER-and PR-breast tumors than in tumors that bore estrogen or progesterone receptors. 6 Since dietary fat can fuel the arachidonic acid pathway and thus the production of tumor-promoting prostaglandins by COX-2, it may be logical that a low-fat diet suppressed the growth of ER-tumors in the WINS study. Women's VF intake and PA may work through other mechanisms, such as suppression of estradiol or insulin levels, and thus may be more effective in ER+ tumors.
The results of the WHEL analysis and its comparison to the WINS study do, of course, prompt some questions. The mortality rate in the WINS study was about 1% to 2%, much less than the overall mortality of 9% in the WHEL study. Reasons for this likely include the overall better prognostic factors in the WINS patients (54% in stage 1) versus the WHEL patients (40% in stage 1) and the shorter observation period: the WINS study reported recurrence rather than mortality. It will be interesting to see if the WINS population can be followed long enough to track survival data to levels comparable to that of the WHEL study and what the impact of the low-fat diet might be on survival; it is important to note that survival and recurrence do not always follow similar patterns. The WINS study team has not commented on obesity or PA, but it would certainly be interesting to see analyses of these variables similar to those done for the WHEL study.
Another study of the WHEL control group indicated a strong relationship between PA and diet. 7 High levels of PA were associated with good compliance with the National Cancer Institute's main diet recommendations: lower fat levels, higher fiber intake, and high VF intake. Could high VF intake and the high level of PA be, to some extent, markers for an overall healthy lifestyle? This certainly seems like a possibility, and it would be interesting to know the survival outcomes of WHEL patients who not only had high VF intake and high levels of PA but also high fiber and low fat consumption. The intercorrelation of health behaviors suggests that the best strategy for survival in breast cancer may be to support patients in adopting a full range of healthful behaviors, building on the basics of VF consumption and PA. This is, of course, the essential model of integrative medicine, and it is indeed exciting to see an article that seriously supports this model with compelling data appearing in the most prominent journal in oncology.
Having assured ourselves that the Journal of Clinical Oncology is heading in the direction of becoming an integrative medicine-based publication, we now consider what the current issue of Integrative Cancer Therapies has to contribute to the field. Our first and longest article is a review by Dr Ling Xu of the Second Military Medical University in Shanghai, China, working with coauthors from the National Institutes of Health, the University of Maryland's Center for Integrative Medicine, and Shanghai University of Traditional Chinese Medicine. The review is a thorough assessment of the uses of traditional Chinese herbal medicine for cancer pain. This is an invaluable summary of the Chinese clinical trial literature on the subject, otherwise inaccessible to most Western readers. The authors critically consider the quality of the clinical trials, which is certainly problematic. Overall, however, this article provides a multitude of suggestions for future research in this area.
The article by Carole Schneider and colleagues at the Rocky Mountain Cancer Rehabilitation institute addresses the important issue of individualization of integrative therapies. In this study, male cancer survivors were given detailed assessments of their physical condition by trained therapists before being provided with an exercise program that was adapted to their specific conditions. I have found that such detailed assessments are critical in clinical oncology practice, where patients may differ radically in their capacities for different forms of exercise. Schneider is especially to be commended for giving an example of an exercise program in the table in her article.
Birendrath Banerjee and colleagues, working with M. Prakash Hande of the National University of Singapore, offer a new look at the stress reduction capacity of yoga in breast cancer patients receiving radiation therapy. They performed a randomized trial of yoga versus a wait-listed, group given counseling. They monitored depression, anxiety, and perceived stress, which all declined in the yoga group relative to controls, as would be expected. They also monitored, however, the incidence of DNA damage in peripheral blood lymphocytes using comet assays. This measure, which had been previously related to stress conditions, provides a window into the effects of stress at the molecular level. This stress effect may be mediated by cortisol levels, catecholamine levels, changes in DNA repair capacity, and other physiological causes. The study is certainly a revealing way to examine how stress can affect the body, and it opens up an area that needs more attention.
Ben Kavoussi and Evan Ross present a short review of the possible anti-inflammatory effects of acupuncture and how they might be mediated through control of the vagus nerve. Our understandings of the mechanisms of acupuncture are expanding through studies of gate-control theory, counterirritation, and a phenomenon known as counterinflammation, in which local inflammations can decrease inflammatory reactions at distant sites. K. J. Tracey has more recently found that the vagus nerve is also responsible for initiating synthesis of several cytokines involved in inflammation. Various interventions, including acupuncture, may affect this cholinergic anti-inflammatory pathway. Kavoussi and Ross explore the implications of this theory for the conduct of sham-controlled trials in acupuncture in an intriguing article.
Neha Trivedi, Upendra Rawal, and Beena Patel from Gujarat University and Gujarat Cancer Research Institute carry forward a compound that has been discussed in the pages of this journal before, andrographolide. Sheeja and Kuttan, who explored the immune effects of this compound, isolated from Andrographis paniculata, currently well known as the cold remedy Kan Jang. Trivedi and coauthors explore the antioxidant and tumor-preventive activities of andrographolide in an animal model of liver tumors induced in mice by the action of an insecticide.
Along with Kuttan, C. Guruvayoorappan presents data on the antiangiogenic properties of β-carotene. This controversial compound does, it seems, have some properties that are useful in tumor suppression, including in vitro and in vivo suppression of angiogenesis and alteration of the cytokine profile as well as inhibiting several transcription factors relevant to cancer. It may be that we will eventually find a beneficial use for β-carotene, possibly alongside multiple other antioxidants that might create an antioxidant rather than an oxidizing environment.
Ralph Moss, our corresponding editor, is not afraid of taking on challenges. While oncologists continue to raise concerns about the use of antioxidants with radiation therapy, especially after the trial of β-carotene and vitamin E with radiation that appeared a few years ago, Moss has gone to the literature and reviewed what has actually been published about antioxidants and radiation therapy. His conclusions do not accord with the current conventional wisdom about antioxidants, and his article is definitely worth reading in the context of the ongoing antioxidant debate. 8 Burton and Arthur Berkson, along with one of our associate editors, Dan Rubin, discuss a situation that is not uncommonly confronted in integrative clinics: the patient who refuses chemotherapeutic treatment of a cancer that should be conventionally treated. In this case, the strategy they used with the lymphoma patient who is the subject of their case report was administration of low-dose naltrexone. Interestingly, there was an April 20, 2007, conference held by the National Cancer Institute titled "Low-Dose Opioid Blockers, Endorphins and Metenkephalin: Promising Compounds for Unmet Medical Needs."
We conclude with an entry in our occasional series "Patient Perspectives." Ann Fonfa is the president of the Annie Appleseed Project, a cancer patient advocacy organization that should be well known to most of us in the field of integrative cancer therapy. Fonfa points out a number of barriers to progress in this area that she has noted in her attendance at cancer meetings. The barriers include a number of subjects that are regularly discussed in this journal, including reductionistic approaches to research in contrast to whole-systems research. It is important for physicians and other health care practitioners as well as researchers to listen to Fonfa and the patients she represents. They express the deep concerns of those whom we serve. Dismissing them leaves us at risk for missing both their acute needs and their authentic, personal understandings of the directions that integrative medicine should pursue.
